Welcome to our dedicated page for WEST PHARMACEUTICAL SERVICES SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WEST PHARMACEUTICAL SERVICES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WEST PHARMACEUTICAL SERVICES's regulatory disclosures and financial reporting.
WEST PHARMACEUTICAL SERVICES INC SVP & Chief Financial Officer Robert W. McMahon reported vesting and settlement of restricted stock units on August 11, 2026. He exercised or converted RSUs into 7,149.205 shares of common stock, and 3,109.19 shares of common stock were delivered or withheld at $351.37 per share for payment of exercise price or tax liability. The remaining common shares from these RSU conversions were retained as direct holdings. The Rule 10b5-1 trading plan checkbox was not selected.
FMR LLC has reported beneficial ownership of 3,559,015.80 shares of WEST PHARMACEUTICAL SVCS INC common stock, representing 5.0% of the class as of June 30, 2026. FMR reports sole dispositive power over these shares and no shared voting or dispositive power.
Within FMR’s reporting group, FMR LLC holds 3,469,427.93 shares with sole voting power and 3,559,015.80 shares with sole dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 3,559,015.80 shares, but no sole or shared voting power. The filing notes that one or more other persons may receive dividends or sale proceeds from these securities, though no single such person has an interest exceeding five percent of the outstanding common stock.
West Pharmaceutical Services reported strong second-quarter 2026 results, with net sales of $872.3 million, up 13.8%, and organic growth of 12.7%. Diluted EPS was $2.15, up 18.1%, while adjusted-diluted EPS rose 28.8% to $2.37 as gross margin expanded to 37.7% and adjusted operating margin to 22.6%.
Growth was led by the Proprietary Products segment, where net sales increased 16.6% to $722.6 million. High-Value Product Components generated $424.1 million, 49% of total sales, and HVP Delivery Devices $131.2 million, supported by strong Biologics and GLP-1 demand. West Vantage net sales were $149.7 million, up 2.0%, though margins were pressured by a cybersecurity incident.
For the first half of 2026, operating cash flow was $213.9 million, capital expenditures $85.9 million, and free cash flow $128.0 million. The company repurchased 1.8 million shares for $454.3 million and declared a quarterly dividend of $0.22 per share. Full-year 2026 guidance was raised to net sales of $3.345–$3.380 billion and adjusted-diluted EPS of $8.85–$9.05, with Q3 2026 net sales expected at $820–$835 million and adjusted-diluted EPS of $2.14–$2.24.
West Pharmaceutical Services, Inc. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd., effective July 14, 2026. The company holds a 49% ownership interest in Daikyo.
The Crosslicense Agreement provides mutual sharing of know-how and cooperation in developing closures, vials, cartridges, syringes and related pharmaceutical packaging and delivery components. Each party may license the other’s know-how, patents and trademarks; Daikyo’s license from West is non-exclusive, while West’s license from Daikyo is exclusive outside Japan, in each case subject to limited exceptions. The arrangement is royalty-free except for a fixed royalty rate on certain patents and non-patented technical information. One Distributorship Agreement grants West exclusive rights to distribute Daikyo products outside Japan, and the other grants Daikyo non-exclusive rights to distribute West products in Japan. Each agreement has a 10-year term and may be terminated earlier under specified circumstances, including mutual consent or a change in control.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services Inc. director Janet Brutschea Haugen reported routine equity-based compensation. She received a grant of 46 Phantom Stock Units tied to common stock, increasing her phantom unit balance to 306.678 units. She also holds 2,113.010 shares of common stock directly, plus 791 restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting under the Deferred Compensation Plan for Outside Directors. Awards of phantom stock units are to be settled in shares of stock upon her termination as a director.
West Pharmaceutical Services announced that Michel Lagarde will become President and Chief Executive Officer and join the Board, effective August 31, 2026, succeeding Eric M. Green, who will retire from his roles on that date. Lead Independent Director Robert F. Friel will become Chair of the Board.
Lagarde’s employment agreement sets an annual base salary of $1,175,000 and a target annual incentive equal to 125% of salary, prorated for 2026. He will receive 2026 long‑term incentive awards valued at $8,611,111 and one‑time inducement equity grants with a maximum aggregate value of $10,000,000, combining performance share units, restricted stock units and stock options.
The agreement provides severance protections, including salary continuation and benefits for certain terminations, and enhanced cash and equity vesting if termination occurs within two years after a change in control. Lagarde will relocate to the company’s Exton, Pennsylvania headquarters and continue West’s focus on injectable drug delivery solutions.
West Pharmaceutical Services, Inc. filed an amended report updating details on a previously disclosed material cybersecurity attack. The company states that core enterprise systems are restored and that manufacturing, receiving and shipping processes have restarted at all sites, with global operations now fully functional.
The intrusion was initially detected on May 4, 2026, with data exfiltration and system encryption confirmed by May 7, 2026. The company reports no unauthorized activity or access has been observed since May 5, 2026. Based on its investigation to date, it believes the incident has not had, and is not reasonably likely to have, a material impact on its 2026 second-quarter and full-year financial guidance.
West Pharmaceutical Services senior vice president Shane Alden Campbell reported routine equity compensation activity involving restricted stock units that convert into common stock on a one-for-one basis. On May 12, 2026, he exercised 473.593 and 295.995 RSUs into common shares, while 134.927 and 84.329 shares were disposed of to cover tax liabilities. These transactions reflect derivative exercises and tax-withholding dispositions rather than open‑market buying or selling.
West Pharmaceutical Services, Inc. reported a material cybersecurity attack that involved data being exfiltrated by an unauthorized party and encryption of certain systems. After detecting the intrusion on May 4, 2026, the company took systems offline globally, notified law enforcement, and engaged external cyber‑forensic experts, including Palo Alto Networks’ Unit 42.
The attack and the company’s containment measures have temporarily disrupted business operations worldwide. Core enterprise systems have been restored and key shipping, receiving, and manufacturing processes have restarted at some sites, with other locations still being brought back online. The company has not yet determined the incident’s material impact on its financial condition or results.